InvestorsHub Logo
Post# of 1030
Next 10
Followers 137
Posts 41656
Boards Moderated 7
Alias Born 01/05/2004

Re: T695 post# 624

Monday, 05/08/2017 8:16:50 AM

Monday, May 08, 2017 8:16:50 AM

Post# of 1030
Durect, Novartis sign $293M U.S. development, marketing deal for Posimir

May 8, 2017 7:31 AM ET

Durect (NASDAQ:DRRX) announces a development and commercialization agreement with Novartis' (NYSE:NVS) Sandoz unit to develop and market its Posimir in the U.S.; shares are halted.

NVS will make a $20M upfront payment to DRRX, with the potential for up to an additional $43M in development and regulatory milestones, up to an additional $230M in sales based milestones, and a tiered double digit royalty on product sales in the U.S.

Posimir is a controlled release injection of bupivacaine intended to provide up to three days of continuous pain relief after surgery.

invest at your own risk, based on your own due diligence, at your own risk tolerance

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent DRRX News